Document is current
Any future updates will be listed below
-
Authors
Lu, Li
Wang, Yue
Ebrahimi, Omid V.
Shen, Qing
Unnarsdóttir, Anna Bára
Hauksdóttir, Arna
Hoffart, Asle
Thordardottir, Edda Bjork
Magnúsdóttir, Ingibjörg
Jakobsdóttir, Jóhanna
Trogstad, Lill
Aspelund, Thor
Fang, Fang
Brandlistuen, Ragnhild E.
Johnson, Sverre Urnes
Valdimarsdóttir, Unnur Anna
Andreassen, Ole A.
Ask, Helga
-
Funding
Funding for this research was provided by:
The Outstanding Clinical Discipline Project of Shanghai Pudong (PWYgy2021-02)
NordForsk (156298, 138929)
Research Council of Norway (324499, 324620)
University of Oslo
- License Information
-
More Information
Article History
Received: 17 October 2024
Accepted: 14 August 2025
First Online: 25 September 2025
Declarations
:
: Ethical approvals were obtained for each participating cohort from national or regional bioethics committees; all participants provided a written informed consent. Ethical approval for Icelandic C-19 Resilience cohort was obtained from the National Bioethics Committee (NBC no. 20–073) as well as the National Data Protection Authority. Ethical approval for Norwegian MAP-19 was obtained from the Regional Committee for Medical Research Ethics (#125510). The establishment of MoBa was based on a license from the Norwegian Data Protection Agency and approval from The Regional Committees for Medical and Health Research Ethics (REK). The MoBa analyses for this project were approved by REK (#127708). The studies were conducted in accordance with the local legislation and institutional requirements.
: Not applicable.
: Author OAA is consultant to the Cortechs.ai and Precision Health, and received speaker’s honoraria from Lilly, BMS, Lundbeck, Otsuka, Janssen and Sunovion. All other authors declare that they have no competing interests.
